LENZ Therapeutics' aceclidine outshines Vuity for presbyopia with better safety and duration. Click for LENZ's market ...

LENZ Therapeutics, a ... 53% of patients showed three lines or more of reading improvement and 81% showed two lines or more. Effects were significant up to seven hours, ...

LENZ Therapeutics, a privately held late-stage clinical company, ... (MOA) is ideally positioned to create a pinhole pupil effect while avoiding myopic shift.

LENZ now has funding from Versant Ventures and RA Capital Management, plus a new leader fresh off a 2020 M&A exit. Eef Schimmelpennink joins from Pfenex, which he led as CEO to a $516 million ...

LENZ Therapeutics (LENZ) announced that the U.S. Food and Drug Administration, FDA, has accepted the Company’s New Drug Application, NDA, for LNZ100 for the treatment of presbyopia, a condition ...